ArticleFrontiers in immunology2025
Decoding HSP90AA1-driven inflammatory signaling in the uveal melanoma microenvironment: an integrated analysis at single-cell resolution.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Decoding key regulators in the uveal melanoma (UVM) tumor microenvironment (TME) is crucial for understanding disease progression and developing novel immunotherapy strategies. This study aims to integrate advanced computational methods and single-cell technologies to identify and validate key molecular regulators mediating inflammatory and immune signal transduction in UVM, and to explore their potential as therapeutic targets. Patients and methods: An integrated strategy was employed, first utilizing a network-based computational screening approach to identify core regulatory genes associated with UVM progression. Subsequently, single-cell RNA-sequencing (scRNA-seq) data were analyzed to precisely delineate the expression profile of the identified key gene, HSP90AA1, across different cell populations in the UVM microenvironment at single-cell resolution. Finally, the functional role of HSP90AA1 was rigorously validated through siRNA-mediated knockdown, Results: Our computational analysis identified HSP90AA1 as a central hub gene. Single-cell analysis revealed that HSP90AA1 is widely expressed across multiple cell types within the UVM tumor microenvironment, particularly in malignant cells, CD8+ T cells, and macrophages. Functional validation confirmed that knockdown of HSP90AA1 significantly suppressed UVM cell proliferation, migration, invasion, and Conclusion: By integrating computational biology screening and single-cell resolution analysis, this study successfully decodes HSP90AA1 as a key regulator of the UVM inflammatory and immune microenvironment. These findings, grounded in single-cell insights and confirmed by rigorous experimental validation, reveal the tumor's intrinsic "chaperone dependency" and highlight HSP90AA1 as a highly promising therapeutic target. Targeting HSP90AA1 may offer a new strategy for modulating the UVM tumor immune microenvironment and overcoming tumor progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.